Biocon launches
ALZUMAb for psoriasis patients in India
Biocon, Asia's premier biotechnology
company, today announced the launch of its first in class novel biologic
ALZUMAb (Itolizumab), the world’s first anti-CD6 monoclonal antibody to be
introduced for treating patients with chronic plaque psoriasis, in India.
ALZUMAb with a unique Mechanism
of Action (MOA) offers superior safety and similar efficacy profile compared to
other existing therapies, and has a long remission period with very low
opportunistic infection rate. Psoriasis is a socially debilitating disease
affecting 2-3 percent of world population
No comments:
Post a Comment